HLS Free Cash Flow Yield vs Book Value Per Share Analysis

HLS Stock

CAD 3.65 0.15 4.29%

HLS Therapeutics financial indicator trend analysis is much more than just examining HLS Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether HLS Therapeutics is a good investment. Please check the relationship between HLS Therapeutics Free Cash Flow Yield and its Book Value Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Free Cash Flow Yield vs Book Value Per Share

Free Cash Flow Yield vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of HLS Therapeutics Free Cash Flow Yield account and Book Value Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between HLS Therapeutics' Free Cash Flow Yield and Book Value Per Share is -0.2. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of HLS Therapeutics, assuming nothing else is changed. The correlation between historical values of HLS Therapeutics' Free Cash Flow Yield and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of HLS Therapeutics are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Free Cash Flow Yield i.e., HLS Therapeutics' Free Cash Flow Yield and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

-0.2

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from HLS Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into HLS Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, HLS Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 12th of December 2024, Sales General And Administrative To Revenue is likely to grow to 0.18, though Tax Provision is likely to grow to (258.4 K).

	2021	2022	2023	2024 (projected)
Total Revenue	60.0M	61.5M	63.1M	56.1M
Interest Expense	7.0M	7.3M	8.7M	9.2M

Total Revenue Interest Expense

HLS Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Cash
Total Assets		-0.01	0.69	0.94	0.99	-0.37	0.23	0.42	-0.54	0.85	0.97	0.43	0.9	0.19	0.62	0.73	0.94	0.45	-0.13	0.08	0.96	-0.34	0.59	0.57	0.0	0.18
Short Long Term Debt Total	-0.01		0.14	-0.16	0.03	-0.31	0.82	0.1	0.3	-0.31	-0.11	-0.16	0.05	0.65	0.0	0.16	-0.09	-0.27	-0.52	-0.69	-0.11	-0.36	0.44	-0.28	0.66	0.64
Other Current Liab	0.69	0.14		0.72	0.67	-0.21	0.23	0.03	0.03	0.53	0.61	0.51	0.8	0.55	0.69	0.26	0.61	-0.22	-0.34	0.08	0.64	-0.29	0.71	-0.03	0.26	0.55
Total Current Liabilities	0.94	-0.16	0.72		0.94	-0.3	0.11	0.2	-0.57	0.92	0.91	0.33	0.78	0.19	0.6	0.67	0.85	0.43	0.01	0.19	0.89	-0.27	0.59	0.6	-0.12	0.19
Total Stockholder Equity	0.99	0.03	0.67	0.94		-0.36	0.25	0.4	-0.53	0.82	0.96	0.35	0.86	0.23	0.58	0.76	0.9	0.45	-0.13	0.06	0.92	-0.33	0.61	0.6	0.05	0.23
Property Plant And Equipment Net	-0.37	-0.31	-0.21	-0.3	-0.36		-0.51	-0.56	0.3	-0.1	-0.4	-0.37	-0.34	-0.19	0.16	-0.26	-0.42	-0.31	0.06	0.5	-0.41	0.98	-0.18	-0.3	0.22	-0.2
Current Deferred Revenue	0.23	0.82	0.23	0.11	0.25	-0.51		0.31	-0.15	-0.01	0.22	-0.15	0.23	0.56	0.12	0.42	0.27	0.06	-0.58	-0.6	0.25	-0.5	0.46	-0.1	0.49	0.56
Net Debt	0.42	0.1	0.03	0.2	0.4	-0.56	0.31		-0.35	0.1	0.48	0.31	0.42	-0.15	-0.22	0.44	0.5	0.37	-0.23	-0.27	0.45	-0.53	-0.14	0.3	0.03	-0.16
Retained Earnings	-0.54	0.3	0.03	-0.57	-0.53	0.3	-0.15	-0.35		-0.68	-0.64	0.15	-0.25	0.15	-0.14	-0.72	-0.63	-0.92	-0.3	-0.17	-0.65	0.12	-0.18	-0.75	0.4	0.15
Accounts Payable	0.85	-0.31	0.53	0.92	0.82	-0.1	-0.01	0.1	-0.68		0.85	0.24	0.7	0.01	0.65	0.65	0.82	0.56	0.12	0.35	0.85	-0.04	0.49	0.58	-0.24	0.01
Non Current Assets Total	0.97	-0.11	0.61	0.91	0.96	-0.4	0.22	0.48	-0.64	0.85		0.42	0.87	0.07	0.58	0.71	0.98	0.54	-0.11	0.11	0.99	-0.35	0.48	0.6	-0.09	0.07
Non Currrent Assets Other	0.43	-0.16	0.51	0.33	0.35	-0.37	-0.15	0.31	0.15	0.24	0.42		0.68	-0.09	0.27	-0.15	0.47	-0.14	0.01	-0.11	0.45	-0.47	0.05	-0.05	-0.28	-0.09
Other Assets	0.9	0.05	0.8	0.78	0.86	-0.34	0.23	0.42	-0.25	0.7	0.87	0.68		0.23	0.69	0.47	0.9	0.17	-0.3	0.04	0.89	-0.37	0.56	0.21	0.1	0.22
Cash And Short Term Investments	0.19	0.65	0.55	0.19	0.23	-0.19	0.56	-0.15	0.15	0.01	0.07	-0.09	0.23		0.23	0.24	0.08	-0.25	-0.3	-0.19	0.1	-0.24	0.84	-0.24	0.59	1.0
Net Receivables	0.62	0.0	0.69	0.6	0.58	0.16	0.12	-0.22	-0.14	0.65	0.58	0.27	0.69	0.23		0.27	0.63	0.01	-0.32	0.33	0.63	0.15	0.63	0.02	0.22	0.23
Common Stock Shares Outstanding	0.73	0.16	0.26	0.67	0.76	-0.26	0.42	0.44	-0.72	0.65	0.71	-0.15	0.47	0.24	0.27		0.66	0.66	-0.13	0.05	0.68	-0.15	0.51	0.64	0.21	0.24
Non Current Liabilities Total	0.94	-0.09	0.61	0.85	0.9	-0.42	0.27	0.5	-0.63	0.82	0.98	0.47	0.9	0.08	0.63	0.66		0.53	-0.15	0.1	0.99	-0.36	0.49	0.5	-0.09	0.08
Inventory	0.45	-0.27	-0.22	0.43	0.45	-0.31	0.06	0.37	-0.92	0.56	0.54	-0.14	0.17	-0.25	0.01	0.66	0.53		0.4	0.12	0.53	-0.14	0.07	0.8	-0.42	-0.24
Other Current Assets	-0.13	-0.52	-0.34	0.01	-0.13	0.06	-0.58	-0.23	-0.3	0.12	-0.11	0.01	-0.3	-0.3	-0.32	-0.13	-0.15	0.4		0.1	-0.12	0.14	-0.21	0.49	-0.76	-0.3
Other Stockholder Equity	0.08	-0.69	0.08	0.19	0.06	0.5	-0.6	-0.27	-0.17	0.35	0.11	-0.11	0.04	-0.19	0.33	0.05	0.1	0.12	0.1		0.13	0.55	0.02	0.08	-0.06	-0.18
Total Liab	0.96	-0.11	0.64	0.89	0.92	-0.41	0.25	0.45	-0.65	0.85	0.99	0.45	0.89	0.1	0.63	0.68	0.99	0.53	-0.12	0.13		-0.35	0.51	0.53	-0.11	0.1
Property Plant And Equipment Gross	-0.34	-0.36	-0.29	-0.27	-0.33	0.98	-0.5	-0.53	0.12	-0.04	-0.35	-0.47	-0.37	-0.24	0.15	-0.15	-0.36	-0.14	0.14	0.55	-0.35		-0.18	-0.17	0.14	-0.24
Total Current Assets	0.59	0.44	0.71	0.59	0.61	-0.18	0.46	-0.14	-0.18	0.49	0.48	0.05	0.56	0.84	0.63	0.51	0.49	0.07	-0.21	0.02	0.51	-0.18		0.09	0.42	0.84
Short Term Debt	0.57	-0.28	-0.03	0.6	0.6	-0.3	-0.1	0.3	-0.75	0.58	0.6	-0.05	0.21	-0.24	0.02	0.64	0.5	0.8	0.49	0.08	0.53	-0.17	0.09		-0.43	-0.24
Intangible Assets	0.0	0.66	0.26	-0.12	0.05	0.22	0.49	0.03	0.4	-0.24	-0.09	-0.28	0.1	0.59	0.22	0.21	-0.09	-0.42	-0.76	-0.06	-0.11	0.14	0.42	-0.43		0.58
Cash	0.18	0.64	0.55	0.19	0.23	-0.2	0.56	-0.16	0.15	0.01	0.07	-0.09	0.22	1.0	0.23	0.24	0.08	-0.24	-0.3	-0.18	0.1	-0.24	0.84	-0.24	0.58

Click cells to compare fundamentals

HLS Therapeutics Account Relationship Matchups

HLS Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	319.7M	303.9M	275.9M	241.7M	209.1M	114.0M
Short Long Term Debt Total	93.1M	107.1M	97.6M	97.3M	87.6M	51.5M
Other Current Liab	21.8M	6.2M	901K	6.0M	1.7M	1.6M
Total Current Liabilities	47.1M	35.6M	27.7M	31.2M	26.7M	18.0M
Total Stockholder Equity	178.2M	169.2M	160.7M	125.3M	97.7M	64.7M
Property Plant And Equipment Net	1.3M	1.4M	1.6M	1.1M	965K	916.8K
Current Deferred Revenue	5.8M	5.1M	4.8M	5.7M	6.6M	6.9M
Net Debt	46.0M	86.5M	76.4M	76.6M	65.7M	69.0M
Retained Earnings	(81.5M)	(101.6M)	(119.9M)	(148.4M)	(175.5M)	(166.7M)
Accounts Payable	13.5M	14.2M	9.3M	11.6M	14.1M	8.9M
Non Current Assets Total	256.6M	258.0M	232.2M	197.3M	165.0M	173.2M
Non Currrent Assets Other	2.2M	2.0M	714K	668K	619K	588.1K
Other Assets	3.2M	3.2M	1.4M	1.1M	1.3M	861.2K
Cash And Short Term Investments	47.1M	20.6M	21.2M	20.7M	22.0M	16.9M
Net Receivables	11.9M	12.5M	11.5M	11.2M	10.7M	11.6M
Common Stock Shares Outstanding	29.4M	31.7M	32.2M	32.4M	32.3M	23.1M
Liabilities And Stockholders Equity	319.7M	303.9M	275.9M	241.7M	209.1M	114.0M
Non Current Liabilities Total	94.3M	99.0M	87.5M	85.1M	84.7M	88.9M
Inventory	2.1M	10.6M	8.9M	8.9M	9.5M	10.0M
Other Current Assets	2.1M	2.2M	2.1M	3.6M	1.9M	1.6M
Other Stockholder Equity	11.5M	11.4M	11.7M	13.8M	13.9M	16.7M
Total Liab	141.5M	134.7M	115.2M	116.3M	111.4M	116.9M
Property Plant And Equipment Gross	1.3M	1.4M	3.5M	3.3M	3.1M	2.9M
Total Current Assets	63.1M	45.9M	43.8M	44.4M	44.1M	32.9M
Accumulated Other Comprehensive Income	(537K)	2.0M	3.0M	(5.3M)	(2.8M)	(2.7M)
Short Term Debt	6.0M	10.1M	12.6M	13.6M	5.2M	4.7M
Intangible Assets	252.1M	253.4M	229.2M	195.0M	162.3M	173.4M
Cash	47.1M	20.6M	21.2M	20.7M	22.0M	18.1M
Common Stock Total Equity	192.7M	210.4M	248.7M	257.4M	296.0M	310.8M
Common Stock	248.7M	257.4M	265.9M	265.2M	262.1M	169.5M
Other Liab	15.7M	5.1M	2.5M	1.4M	1.2M	1.2M
Net Tangible Assets	(73.9M)	(84.2M)	(68.4M)	(69.7M)	(80.2M)	(84.2M)
Long Term Debt	86.6M	96.2M	84.1M	83.3M	82.0M	86.2M
Capital Surpluse	11.5M	11.4M	11.7M	13.8M	15.9M	10.3M
Property Plant Equipment	1.3M	1.4M	1.6M	1.1M	1.3M	928.3K
Long Term Debt Total	87.1M	97.0M	85.0M	83.8M	96.3M	91.3M
Non Current Liabilities Other	10.5M	2.6M	1.9M	817K	1.8M	1.7M
Cash And Equivalents	47.1M	20.6M	21.2M	20.7M	18.7M	20.9M

Pair Trading with HLS Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against HLS Stock

0.31

LQWD

LQwD FinTech Corp

Pair Corr

The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.

The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in HLS Stock

Balance Sheet is a snapshot of the financial position of HLS Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. HLS Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of HLS Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which HLS currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

HLS Free Cash Flow Yield vs Book Value Per Share Analysis

Free Cash Flow Yield vs Book Value Per Share

Free Cash Flow Yield vs Book Value Per Share Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Book Value Per Share

HLS Therapeutics fundamental ratios Correlations

HLS Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

HLS Therapeutics fundamental ratios Accounts

Pair Trading with HLS Therapeutics

Moving against HLS Stock

Other Information on Investing in HLS Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Assets Total
Total Liab	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Non Current Liabilities Total	+ 0.98	Non Current Assets Total

Inventory	- 0.92	Retained Earnings
Intangible Assets	- 0.76	Other Current Assets
Short Term Debt	- 0.75	Retained Earnings
Common Stock Shares Outstanding	- 0.72	Retained Earnings
Other Stockholder Equity	- 0.69	Short Long Term Debt Total
Accounts Payable	- 0.68	Retained Earnings